Abingdon Health

Last updated

Abingdon Health
Founded1 January 2008  OOjs UI icon edit-ltr-progressive.svg
Headquarters
York   OOjs UI icon edit-ltr-progressive.svg
,
United Kingdom  OOjs UI icon edit-ltr-progressive.svg
Products Lateral flow assay

Abingdon Health is a British manufacturer of lateral flow assay diagnostic tests, sometimes called rapid tests, lateral flow immunoassays (LFIA), lateral flow tests (LFT) or quick tests. [1] Since its formation in 2008, Abingdon Health has developed and manufactured lateral flow rapid tests across multiple industries. Headquartered in York, UK, with an additional office in Doncaster, UK.

Contents

History

2008:Founded by Dr Chris Hand and Chris Yates.

2012: Acquisition of major stake in Forsite Diagnostics Ltd (Forsite); a spin-out from the UK government's Food and Environment Research Agency (now known as Animal and Plant Health Agency). [2]

2015: Dr Chris Hand and Chris Yates are appointed chairman and Chief Executive respectively

2017: Abingdon takes full ownership of Forsite Diagnostics, and relocates the Group's headquarters to Forsite's York facility.

2019: Growth capital investment by the Northern Powerhouse Investment Fund managed by Mercia Asset Management. [3]

2020: Acquisition of the Doncaster manufacturing facility from Concepta PLC.

2020: IPO of Abingdon Health on the AIM market of the London Stock Exchange.

2020-2022: Abingdon's COVID-19 pandemic response is explained in more detail in the ‘Response to COVID-19 pandemic’ section below.

2022: Launch of Abingdon Simply Test range of self-tests. [4]

Lateral flow tests made by Abingdon Health

Abingdon Health develops and manufactures tests on behalf of its contract customers and has produced and commercialised its own products. Abingdon Health has developed and manufactured sandwich (Non-Competitive) and Inhibition (Competitive) lateral flow immunoassays in areas such as COVID-19, Sexual Health, Fertility, Animal Health, Plant Health, to name a few. Abingdon Health works with numerous clients in the development and manufacture of LFTs. Examples include collaborations with Bioporto, [5] Vatic Health and DeepVerge. [6] A collaboration was also announced in May 2022 with a European client for the manufacture of antigen test components. [7]

In 2015 Abingdon Health launched Seralite [8] a rapid diagnostic device for the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in serum. The company also produces PCRD and PCRD FLEX: [9] lateral flow tests designed to detect nucleic acid following isothermal amplification with technologies such as Loop-mediated isothermal amplification (LAMP) or Recombinase polymerase amplification (RPA), for example. In addition the Abingdon Health owns and manufactures the Pocket Diagnostic brand. A range of tests designed to detect important and commercially damaging plant pathogens such as Phytophthora and Potato virus Y. [10]

Response to COVID-19 pandemic

At the start of the COVID-19 pandemic, Abingdon Health responded to the British government's 'call to arms' to produce a UK-made COVID-19 rapid antibody test. The company initiated the development of AbC-19 rapid antibody test, a test for the presence of neutralising IgG antibodies against the SARS-CoV-2 spike protein. As part of the programme of work, Abingdon Health led UK Rapid Test Consortium group [11] which was a number of UK companies working collaboratively to manufacture tests to meet the government's anticipated demand. Test development commenced in early 2020 with AbC-19 achieving CE marking for professional use across the United Kingdom and the European Union in July 2020. [12]

In October 2020 the UK government announced the signing of a deal with Abingdon Health for the supply of up to ten million AbC-19 rapid antibody tests, with an initial order of one million tests. [13] These one million tests were delivered in full in January 2021, but initially the Department of Health and Social Care (DHSC) refused to pay for them, citing the Judicial Review as one of the reasons for this. [14] The DHSC indicated in January 2021 that they would not be ordering any further tests from the supply agreement, citing the reason being because the Medicines and Health Regulatory Agency would not approve the tests for home use due to DHSC not providing a use case based on a link between a spike antibody levels and immunity to COVID-19. [15] On 28 June 2022, Abingdon Health announced that it had reached a settlement agreement with the DHSC on the outstanding invoices payable by DHSC for lateral flow tests and component stock. [16]

In March 2021, the UK Biobank included the AbC-19 rapid antibody test in a Coronavirus self-test antibody study to investigate the long-term health effects of SARS-CoV-2 infection ("Long COVID"). [17] In April 2021, AbC-19 was paired with a mobile app to provide an antibody certificate solution. [18] A semi-quantitative version of AbC-19 was launched in December 2021. [19]

Judicial Review

The Good Law Project (GLP) challenged the Secretary for Health and Social Care, claiming the COVID testing contracts with Abingdon Health were unlawful because they were not advertised nor open to competition, and the correct procurement process was bypassed, amongst other allegations. [20] The Judicial Review was heard on 3 to 5 May 2022.

On conclusion of the judicial review hearing, Abingdon Health published the following statement in May 2022, "We and the Department of Health and Social Care (DHSC) provided strong arguments for dismissal at the judicial review hearing this week. Our position was clear: this was a straightforward purchase of goods/services by a public body from an established LFT provider on normal market terms. Nothing more! We stood up to offer our expertise in LFT development and manufacture at a time of national emergency and pandemic. In August 2021, we published our Detailed Grounds of Resistance submission to the court to address the factual inaccuracies being raised in this case." [21]

"All Claims dismissed..."

On 7 October 2022 the High Court ruled that the contracts were lawful. "Mr Justice Waksman ruled in favour of the DHSC on all grounds, including lack of state aid to Abingdon Health and dismissed all claims brought by the GLP". [22]

Related Research Articles

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Green Oaks, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

<span class="mw-page-title-main">Lateral flow test</span> Immunochromatographic testing devices

A lateral flow test (LFT), is an assay also known as a lateral flow device (LFD), lateral flow immunochromatographic assay, or rapid test. It is a simple device intended to detect the presence of a target substance in a liquid sample without the need for specialized and costly equipment. LFTs are widely used in medical diagnostics in the home, at the point of care, and in the laboratory. For instance, the home pregnancy test is an LFT that detects a specific hormone. These tests are simple and economical and generally show results in around five to thirty minutes. Many lab-based applications increase the sensitivity of simple LFTs by employing additional dedicated equipment. Because the target substance is often a biological antigen, many lateral flow tests are rapid antigen tests.

<span class="mw-page-title-main">FIND, the global alliance for diagnostics</span> Swiss global health nonprofit organization

FIND is a global health non-profit based in Geneva, Switzerland. FIND functions as a product development partnership, engaging in active collaboration with over 150 partners to facilitate the development, evaluation, and implementation of diagnostic tests for poverty-related diseases. The organisation's Geneva headquarters are in Campus Biotech. Country offices are located in New Delhi, India; Cape Town, South Africa; and Hanoi, Viet Nam.

<span class="mw-page-title-main">Randox</span> UK diagnostics company

Randox is a Northern Irish health and toxicology company in the in vitro diagnostics industry headquartered in Crumlin, County Antrim, Northern Ireland, owned by Peter FitzGerald. The company develops diagnostic solutions for hospitals, clinical, research and molecular labs, food testing, forensic toxicology, veterinary labs and life sciences. It develops, manufactures and markets reagents and equipment for laboratory medicine, with a distribution network of 145 countries. Randox is the biggest polymerase chain reaction testing provider in the United Kingdom and Republic of Ireland. Randox received three contracts by the Department of Health and Social Care without having to compete for a tender.

Flow-through tests or immunoconcentration assays are a type of diagnostic assay that allows users to test for the presence of a biomarker, usually a specific antibody, in a sample such as blood. They are a type of point of care test, designed to be used by a healthcare provider at patient contact. Point of care tests often allow for rapid detection of a specific biomarker without specialized lab equipment and training; this aids in diagnosis and allows therapeutic action to be initiated more quickly. Flow-through tests began development in the early 1980s and were the first type of immunostrip to be developed, although lateral flow tests have subsequently become the dominant immunostrip point of care device.

DiaSorin is an Italian multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics and since July 2021, it is also active in the Life Science business. The group was founded in 2000 and is headquartered in Saluggia, Italy. Its production is at several plants located in Europe and the United States: Saluggia and Gerenzano (Italy), Dietzenbach (Germany), Stillwater, Minnesota (US), Dartford (UK). Following the acquisition of Luminex, the company acquired five additional production plants located in the United States and in Canada (Toronto). The company is a constituent of the FTSE MIB index.

QuidelOrtho Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide.

<span class="mw-page-title-main">Rapid diagnostic test</span>

A rapid diagnostic test (RDT) is a medical diagnostic test that is quick and easy to perform. RDTs are suitable for preliminary or emergency medical screening and for use in medical facilities with limited resources. They also allow point-of-care testing in primary care for things that formerly only a laboratory test could measure. They provide same-day results within two hours, typically in approximately 20 minutes.

<span class="mw-page-title-main">Rapid antigen test</span> Fast medical lateral flow test

A rapid antigen test (RAT), sometimes called a rapid antigen detection test (RADT), antigen rapid test (ART), or loosely just a rapid test, is a rapid diagnostic test suitable for point-of-care testing that directly detects the presence or absence of an antigen. RATs are a type of lateral flow test detecting antigens, rather than antibodies or nucleic acid. Rapid tests generally give a result in 5 to 30 minutes, require minimal training or infrastructure, and have significant cost advantages. Rapid antigen tests for the detection of SARS-CoV-2, the virus that causes COVID-19, have been commonly used during the COVID-19 pandemic.

<span class="mw-page-title-main">COVID-19 testing</span> Diagnostic testing for SARS-CoV-2 virus infection

COVID-19 testing involves analyzing samples to assess the current or past presence of SARS-CoV-2. The two main types of tests detect either the presence of the virus or antibodies produced in response to infection. Molecular tests for viral presence through its molecular components are used to diagnose individual cases and to allow public health authorities to trace and contain outbreaks. Antibody tests instead show whether someone once had the disease. They are less useful for diagnosing current infections because antibodies may not develop for weeks after infection. It is used to assess disease prevalence, which aids the estimation of the infection fatality rate.

<span class="mw-page-title-main">UK Health Security Agency</span> Executive agency in UK health system

The UK Health Security Agency (UKHSA) is a government agency in the United Kingdom, responsible since April 2021 for England-wide public health protection and infectious disease capability and replacing Public Health England. It is an executive agency of the Department of Health and Social Care (DHSC).

Operation Moonshot was a UK government programme to introduce same-day mass testing for COVID-19 in England as a way of enabling large gatherings of people to take place in that country while maintaining control over the virus. According to the British Medical Journal, the programme aimed to deliver 10 million tests per day by 2021.

<span class="mw-page-title-main">Casirivimab/imdevimab</span> Antiviral combination medication

Casirivimab/imdevimab, sold under the brand name REGEN‑COV among others, is a combination medicine used for the treatment and prevention of COVID‑19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. It is also available as a co-formulated product. It was developed by the American biotechnology company Regeneron Pharmaceuticals.

The AbC-19 rapid antibody test is an immunological test for COVID-19 exposure developed by the UK Rapid Test Consortium and manufactured by Abingdon Health. It uses a lateral flow test to determine whether a person has IgG antibodies to the SARS-CoV-2 virus that causes COVID-19. The test uses a single drop of blood obtained from a finger prick and yields results in 20 minutes. The sensitivity of this test is 98.03% while the specificity is 99.56%. This test is paired with an easy-to-use mobile app which allows a trained professional to generate an antibody test certificate for storing on a person's smartphone.

The UK Rapid Test Consortium (UK-RTC) is a United Kingdom industry consortium created to produce a lateral flow rapid test for COVID-19. Rapid tests are a form of COVID-19 testing technology that was originally developed from significant investment by the United Kingdom government to develop new forms of COVID-19 testing that provided advantages over existing forms such as PCR. Its members include Abingdon Health, BBI Solutions, CIGA Healthcare, Omega Diagnostics, and Oxford University.

In response to the COVID-19 pandemic in the United Kingdom, the British government decided in March 2020 to rapidly place contracts and recruit a number of individuals. Shortages of personal protective equipment (PPE) were a particular political issue for the second Johnson ministry. This led to the awarding of a number of contracts without a competitive tendering process, and friends of political figures and people who had made political donations were quickly given contracts. As a result, accusations of cronyism were made against the government.

CIGA Healthcare is a British manufacturer of lateral flow assay diagnostic tests. It is under contract to the British government for the supply of AbC-19 rapid antibody tests, a test for the presence of IgG antibody against the SARS-CoV-2 spike protein, as part of the UK Rapid Test Consortium program.

<span class="mw-page-title-main">COVID-19 rapid antigen test</span> Diagnostic test for a SARS-CoV-2 infection

COVID-19 rapid antigen tests or RATs, also frequently called COVID-19 lateral flow tests or LFTs, are rapid antigen tests used to detect SARS-CoV-2 infection (COVID-19). They are quick to implement with minimal training, cost a fraction of other forms of COVID-19 testing, and give users a result within 5–30 minutes. RATs have been used in several countries as part of mass testing or population-wide screening approaches. Many RATs can be used for self-testing, in which an individual "collects their own specimen… and interpret[s] their test result themselves".

<span class="mw-page-title-main">United Kingdom responses to the COVID-19 pandemic</span> Actions by the United Kingdom regarding the COVID-19 pandemic

The United Kingdom's response to the COVID-19 pandemic consists of various measures by the healthcare community, the British and devolved governments, the military and the research sector.

References

  1. ↑ "Abingdon Health announces its latest expansion and additional manufacturing capacity". Lifescience Industry News. 18 June 2020. Retrieved 12 November 2020.
  2. ↑ "Abingdon Health Ltd Acquires Controlling Stake in Forsite Diagnostics Ltd". BioSpace. Retrieved 27 June 2012.
  3. ↑ "Funds Overview". Mercia Asset Management.
  4. ↑ "Occupier Update: Welcome to Abingdon Simply Test!". York Biotech Campus. Retrieved 21 July 2022.
  5. ↑ "Abingdon Health strikes manufacturing and supply deal with Bioporto". med-technews.com. 6 July 2021. Retrieved 6 July 2021.
  6. ↑ "Abingdon Health signs MOU with Vatic Health and DeepVerge". ukinvestormagazine.co.uk. 29 March 2022. Retrieved 29 March 2022.
  7. ↑ "York-based Abingdon Health signs 'significant' contract to manufacture lateral flow device components". YorkshirePost.co.uk. Retrieved 17 May 2022.
  8. ↑ "Commercial Launch of Rapid Diagnostic Device for Multiple Myeloma". www.newswise.com. Retrieved 19 May 2021.
  9. ↑ PCRD: Rapid nucleic acid detection for point of care molecular testing , retrieved 19 May 2021
  10. ↑ "About Us". Pocket Diagnostic. Retrieved 17 May 2022.
  11. ↑ Symon, Ken (19 October 2020). "Medical diagnostics company signs deal on delivery of COVID-19 tests". businessInsider. Retrieved 12 November 2020.
  12. ↑ Hedges, Emma (31 July 2020). "UK COVID-19 rapid antibody tests approved for professional use & commercial distribution". Pharmafield. Retrieved 19 May 2021.
  13. ↑ "Government invests in UK-developed antibody tests from UK Rapid Test Consortium". GOV.UK. Retrieved 12 November 2020.
  14. ↑ "Covid test manufacturer cuts 60 jobs after Government refuses to pay millions of pounds it owes". TheBusinessDesk.com. Retrieved 30 May 2022.
  15. ↑ Shubber, Kadhim; Gross, Anna. "Lead Covid antibody test developer has government orders cancelled". Financial Times. Nikkei Inc. Retrieved 11 May 2022.
  16. ↑ "Settlement agreement signed with the DHSC". London Stock Exchange. Retrieved 28 June 2022.
  17. ↑ "The phase 2 study uses the AbC-19TM Rapid test kit". www.ukbiobank.ac.uk/. Archived from the original on 20 March 2021. Retrieved 1 May 2021.
  18. ↑ "Abingdon Health Notes Announcement by UK-RTC on providing an Antibody Certificate using smartphone App technology". www.globenewswire.com/ (Press release). 19 April 2021. Archived from the original on 10 May 2021. Retrieved 11 May 2021.
  19. ↑ "Yorkshire lab launches finger-prick Covid test". YorkshirePost.co.uk. Retrieved 16 December 2021.
  20. ↑ "Civil servants called UK Covid testing scheme 'unlegit', court hears". TheGuardian.com . 3 May 2022.
  21. ↑ "Response to judicial review hearing". LinkedIn. Abingdon Health. Retrieved 6 May 2022.
  22. ↑ https://www.thebusinessdesk.com/yorkshire/news/2100354-court-finds-government-contracts-with-medical-tests-maker-were-lawful
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.